Titlebook: Heart Failure; David S. Feldman,Paul Mohacsi Book 2019 Springer Nature Switzerland AG 2019 Cardiomyopathies.Cardiovascular pharmacotherap.

漏出

書目名稱Heart Failure影響因子(影響力)




書目名稱Heart Failure影響因子(影響力)學(xué)科排名




書目名稱Heart Failure網(wǎng)絡(luò)公開度




書目名稱Heart Failure網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Heart Failure被引頻次




書目名稱Heart Failure被引頻次學(xué)科排名




書目名稱Heart Failure年度引用




書目名稱Heart Failure年度引用學(xué)科排名




書目名稱Heart Failure讀者反饋




書目名稱Heart Failure讀者反饋學(xué)科排名

四溢

Inter- and Intracellular Mechanisms of Cardiac Remodeling, Hypertrophy and Dysfunctionardiac remodeling, how they relate to cardiac disease and how they develop as a result of differential activation of signaling circuits within and between myocardial cells. We also address the regulation of cardiac contractility and cardiac metabolism and the way it changes in heart failure. We demo

書法

ADAGE

Comorbidities and Co-Existing Conditions in Heart Failure Around Pregnancyof women who develop cardiac problems during pregnancy [1]. Indeed, pregnancy challenges the cardiovascular system and may lead to disease states such as hypertensive complications with its severe forms preeclampsia and the HELLP syndrome (H: hemolysis, EL: elevated liver enzymes. low platelets coun

喃喃訴苦

Lyme-disease

decode

Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, with reduced left-ventricular ejection fraction (LVEF). Inhibition of the renin-angiotensin-aldosteron system (RAAS) is one of the key treatment strategies in these patients. ACE-inhibition has been introduced first and is the standard to start medication reducing events in heart failure with reduc

Culmination

Pharmacotherapy in Heart Failure (II): Beta Adrenergic Blocking Drugs, Ivabradine, Hydralazine and Nm as the “fight or flight response” which became activated to react to short bursts of activity associated with “pain, hunger, fear or rage.” The principal responses seen in the cardiovascular system are an increase in heart rate and myocardial contractility, an increase in peripheral vasoconstricti

托運

Device Therapy in the Heart Failure Study, HF increased overall and SCD mortality fivefold [1]. In patients with Class II or III HF, the mode of death is more likely be to “sudden” while in patients with Class IV HF, it is more likely to be due to pump failure [2]. The most common cause of SCD is the degeneration of ventricular tachy

Capitulate